ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).
Se Hoon Park(Samsung Medical Center), Won Ki Kang(Samsung Medical Center), Min Gew Choi(Samsung Medical Center), Tae Sung Sohn(Samsung Medical Center), Boram Han(Hallym University Medical Center), Jeeyun Lee(Samsung Medical Center), Do Hoon Lim(Samsung Medical Center), Jun Ho Ji(DongKook Pharmaceutical (South Korea)), Jae-Moon Bae(Samsung Medical Center), Ji Yeong An(Samsung Medical Center), Sung Yong Oh(Korea University Medical Center), Dae Young Zang(Second Affiliated Hospital of Dalian Medical University), Jun Ho Lee(Soonchunhyang University Hospital Seoul), Seung Kim(Samsung Medical Center), Dongbok Shin(Gachon University Gil Medical Center), Jung Hoon Kim(Gyeongsang National University Hospital), Kyoung Mee Kim(Samsung Medical Center), Tae Gyu Kim(Samsung (South Korea)), Sung Kim(Samsung Medical Center), In Gyu Hwang(Chung-Ang University Hospital)
Cited by 79
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Improved Quality of Life Outcomes After Laparoscopy-Assisted Distal Gastrectomy for Early Gastric Cancer
|Annals of Surgery|2008|609